zanubrutinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitors	5353	1691249-45-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: zanubrutinib BGB-3111 brukinsa	BRUKINSA (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth. Molecular weight: 471.56 Formula: C27H29N5O3 CLOGP: 2.85 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 102.48 ALOGS: -4.66 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

zanubrutinib
BGB-3111
brukinsa

BRUKINSA (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth.

Molecular weight: 471.56
Formula: C27H29N5O3
CLOGP: 2.85
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 102.48
ALOGS: -4.66
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 14, 2019	FDA	BEIGENE USA INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EL03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Bruton's tyrosine kinase (BTK) inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D047428	Protein Kinase Inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Mantle cell lymphoma	indication	443487006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.85	acidic
pKa2	2.64	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
80MG	BRUKINSA	BEIGENE	N213217	Nov. 14, 2019	RX	CAPSULE	ORAL	Nov. 14, 2024	NEW CHEMICAL ENTITY
80MG	BRUKINSA	BEIGENE	N213217	Nov. 14, 2019	RX	CAPSULE	ORAL	Nov. 14, 2026	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN	INHIBITOR	IC50	9.52		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
4038969	VANDF
C4727614	UMLSCUI
BA0	PDB_CHEM_ID
CHEMBL3936761	ChEMBL_ID
D11422	KEGG_DRUG
C000629551	MESH_SUPPLEMENTAL_RECORD_UI
135565884	PUBCHEM_CID
10555	INN_ID
AG9MHG098Z	UNII
9861	IUPHAR_LIGAND_ID
DB15035	DRUGBANK_ID
2262435	RXNORM
326780	MMSL
37672	MMSL
d09435	MMSL
018195	NDDF
830103007	SNOMEDCT_US
830162004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BRUKINSA	HUMAN PRESCRIPTION DRUG LABEL	1	72579-011	CAPSULE, GELATIN COATED	80 mg	ORAL	NDA	30 sections